TSI LLC is a biotechnology startup founded in 2004, specializing in pioneering a groundbreaking thrombolytic, M5, which offers superior efficacy with minimal bleeding risk. The company also offers consulting and project management services focused on process improvement through the tools and methodology of Lean Six Sigma.
The latest significant milestone for TSI LLC was a $7.50M Venture Round investment on 12 January 2012. While details about the investors and the location of the company's headquarters were not available, this investment signifies a key vote of confidence in the potential of the company's innovative approach to thrombolytic treatment and process improvement consulting services.
Overall, TSI LLC presents an intriguing proposition within the biotechnology industry, with its focus on cutting-edge medical solutions and value-driven consultancy services. The recent venture round investment further underscores the confidence in the company's potential for growth and impact within the industry.
